IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v8y2024i5d10.1007_s41669-024-00497-4.html
   My bibliography  Save this article

Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy

Author

Listed:
  • Jonathan Salcedo

    (Takeda Pharmaceuticals U.S.A., Inc.)

  • Daniel Hill-McManus

    (Putnam Associates)

  • Chloë Hardern

    (Putnam Associates)

  • Oyin Opeifa

    (Putnam Associates)

  • Raffaella Viti

    (Takeda Italy S.p.A.)

  • Ludovica Siviero

    (Takeda Italy S.p.A.)

  • Antonio Saverio Roscini

    (Takeda Italy S.p.A.)

  • Gennaro Martino

    (Takeda Italy S.p.A.)

Abstract

Background Today, there are many treatment options available for the management of ulcerative colitis, creating challenges in selecting the most efficacious and cost-effective treatment sequences. Treatments in the anti-tumor necrosis factor alpha (TNFα) therapeutic class, as well as vedolizumab, are widely used and endorsed as first-line options according to treatment guidelines. The aim of this study was to compare treatment sequences involving vedolizumab and the anti-TNFα treatment adalimumab in terms of cost-effectiveness in the treatment of moderately to severely active ulcerative colitis in Italy. Methods A cost-effectiveness model comparing treatment sequences within the Italian National Health Service in terms of costs and quality-adjusted life years (QALYs) with a lifetime horizon was developed. The analysis focused on the relative positioning of vedolizumab and adalimumab, leveraging the results of the landmark head-to-head VARSITY clinical trial as key inputs. The robustness of the results was investigated through a range of sensitivity and scenario analyses. Results The strategy of vedolizumab as a first-line advanced therapy followed by adalimumab was associated with higher costs and health benefits compared with first-line adalimumab followed by vedolizumab. The incremental cost-effectiveness ratio was €16,146/QALY, which was found to be robust to changes to inputs associated with areas of high uncertainty. Conclusion This economic evaluation estimated a 94% probability that vedolizumab as a first-line advanced therapy is cost-effective at a threshold of €33,004/QALY when compared with first-line adalimumab sequences. Using clinical trial evidence to inform the efficacy of second-line treatments estimated that the effectiveness of anti-TNFα treatments is not substantially reduced by vedolizumab exposure.

Suggested Citation

  • Jonathan Salcedo & Daniel Hill-McManus & Chloë Hardern & Oyin Opeifa & Raffaella Viti & Ludovica Siviero & Antonio Saverio Roscini & Gennaro Martino, 2024. "Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy," PharmacoEconomics - Open, Springer, vol. 8(5), pages 701-714, September.
  • Handle: RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00497-4
    DOI: 10.1007/s41669-024-00497-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-024-00497-4
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-024-00497-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00497-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.